GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Summary of Product Characteristics last updated on the eMC: 19/10/2011
SPC Timentin 0.8 G, 1.6 G, 3.2 G

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 19/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   03-Oct-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



6.5

Clear Type I or Type III glass vials fitted with a chlorobutyl rubber bung and an aluminium seal. Supplied in packs of four vials.

10.

Updated with new date of revision of text

Updated on 18/02/2009 and displayed until 19/10/2011
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   17-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.8 - Amendments to renal effects section (now reads renal and urinary effects)

Section 10 - Date changed to date of approval
Updated on 29/07/2008 and displayed until 18/02/2009
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   21-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.2 - Amendments to children's dosage

Section 10 - Date changed to date of approval
Updated on 13/07/2007 and displayed until 29/07/2008
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.5 - update to this section with regard to interactions with oral contraceptives and methotrexate
Section 10 - update date to 10 July 2007
Updated on 16/02/2007 and displayed until 13/07/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441

Updated on 06/12/2004 and displayed until 16/02/2007
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
Updated on 05/08/2003 and displayed until 06/12/2004
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 23/07/2003 and displayed until 05/08/2003
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.8 - Undesirable Effects
Updated on 10/03/2003 and displayed until 23/07/2003
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 27/09/2002 and displayed until 10/03/2003
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 05/08/2001 and displayed until 27/09/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 01/09/2000 and displayed until 05/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 01/09/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   potassium clavulanate
   ticarcillin sodium